Suchergebnisse

PubPharm (178)

1

Trastuzumab emtansine for residual invasive HER2-positive breast cancer

enthalten in: The New England journal of medicine | 2019

von Minckwitz, G. | Huang, C. | Mano, M. | +26

2

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial

enthalten in: Journal of the American Academy of Dermatology | March 17, 2019

von Ständer, S. | Weisshaar, E.

3

IL6 shapes an inflammatory microenvironment and triggers the development of unique types of cancer in end-stage kidney

enthalten in: Anticancer research | 2019

von Peterfi, L. | Yusenko, M. | Kovacs, G.

4

The caries-related cost and effects of a tax on sugar-sweetened beverages

enthalten in: Public health | 16 March 2019

von Jevdjevic, M. | Trescher, A. | Rovers, M. | +1

5

Sepsis in mechanically ventilated patients with spinal cord injury : a retrospective analysis

enthalten in: Spinal cord | 2019

von Weiterer, S. | Frick, S. | Lichtenstern, C. | +5

6

Gender differences in the diagnostic performance of machine learning coronary CT angiography-derived fractional flow reserve -results from the MACHINE registry

enthalten in: European journal of radiology | 2019

von Baumann, S. | Renker, M. | Schoepf, U. | +18

7

Cardiovascular mortality attributable to dietary risk factors in 51 countries in the WHO European Region from 1990 to 2016 : a systematic analysis of the Global Burden of Disease Study

enthalten in: European journal of epidemiology | 2019

von Meier, T. | Gräfe, K. | Senn, F. | +6

8

Patient Experience with Primary Care Physician and Risk for Hospitalization in Hispanics with CKD

enthalten in: Clinical journal of the American Society of Nephrology : CJASN | 2018

von Cedillo-Couvert, E. | Hsu, J. | Ricardo, A. | +12

CommentIn: Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1619-1620. - PMID 30337325

9

Hot-spot KIF5A mutations cause familial ALS

enthalten in: Brain | 12 January 2018

von Brenner, D. | Yılmaz, R. | Müller, K. | +37

10

Ten-year results of intense dose-dense chemotherapy show superior survival compared to a conventional schedule in high-risk primary breast Cancer : final results of AGO phase III iddEPC trial

enthalten in: Annals of oncology | 2018

von Möbus, V. | Jackisch, C. | Lueck, H. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]